JohnPatrickStoutenburgMD

Oncology • Glens Falls, NY

Physician

Join to view full profile

Dr. Stoutenburg is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stoutenburg's full profile

Already have an account?

Office
100 Park St
Cr Wood Cancer Center
Glens Falls, NY 12801
Phone+1 518-926-6620

Fax+1 518-926-1954

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2002 - 2005
University of North Carolina HospitalsResidency, Internal Medicine, 1999 - 2002
SUNY Upstate Medical UniversityClass of 1999

Certifications & Licensure

NY State Medical License 2002 - 2025
NC State Medical License 1999 - 2002
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery Start of enrollment: 2010 Apr 05
Active, not recruiting
Phase 3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

275 citations
Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma
Giovanni C. Cesana, Gail DeRaffele, Seth Cohen, Dorota Moroziewicz, Josephine Mitcham
Journal of Clinical Oncology. 2006-03-01
3 citations
Antiemetic studies on the NK1 receptor antagonist aprepitant.
John P. Stoutenburg, Harry Raftopoulos
Journal of the National Comprehensive Cancer Network. 2004-09-01
13 citations
Initial Clinical Response Predicts Outcome and Is Associated With Dose Schedule in Metastatic Melanoma and Renal Cell Carcinoma Patients Treated With High-Dose Interle...
Kathryn Spanknebel, Kenneth Cheung, John P. Stoutenburg, Karl S. Hurst-Wicker, Charles S. Hesdorffer
Annals of Surgical Oncology. 2004-02-01

Press Mentions

Glens Falls Hospital Raising Money to Expand Oncology PharmacyAugust 10th, 2015